Outcome of Board Meeting

October 30, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Outcome of the Board Meeting Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that based on the recommendation of the Audit Committee, the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the second quarter and half year ended on September 30, 2026. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026. The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com A Press Release on financial results which is being submitted to the media, is also enclosed herewith. The Board meeting commenced at 03:30 p.m. and concluded at 04:40 p.m. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a Walker Chandiok &Co LLP Walker Chandiok & Co LLP Block No. DASth Floor, Cabin No. A8 to A0 “West Gate” Near YMCA Club, S.G Highway, Sarkhej Road, Ahmedabad-380015 Gujarat, India Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obiigations and Disciosure Requirements) Reguiations, 2015 (as amended) To the Board of Directors of CORONA Remedies Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of CORONA Remedies Limited (Formerly known as CORONA Remedies Private Limited) (‘the Company’) for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations’). 2. The Statement, which is the responsibility of the Company’s management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that right be identified in an audit. Accordingly, we do not express an audit opinion. ZERep Rec ‘Cy ha fered Accountants Walker Chandiok & Co LLP s registered with limited liability with identification OffesIn Abmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennal, Debradun, Goa, Gurugram, Guaahat, Hyderabad, Indore, number AAC-2085 and has its registered Kochi, Kokata, Mumbal, New Delhi, Noida and Pune. office at L41, Connaught Circus, Outer Circle, New Delri, 110001, India Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)(cont’d) 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 30 September 2025 and audit of standalone financial results for the year ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who has expressed unmodified conclusion vide their review report dated 02 January 2026 and unmodified opinion vide their audit report dated 11 May 2026, respectively, whose reporis have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 > AL Mehufkumar Sharadkumar Janani Partner Membership No. 118617 UDIN : 26118617HEJLGT5745 Place : Ahmedabad Date : 30 October 2026 Charered Accountants Walker Chandiok & Co LLP is registered vith limited liability with identification Offceisn Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Defradun, Goa, Gurugram, Guwahat, Hyderebad, Indore, number AAC-2085 and has its registered Koehi, Kokt Mumbai, New Del, Noida and Pune office at L41, Connaught Circus, Outer Circle, New Delhi, 110001, India CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) Regd. Office: CORONA House, C - Mondeal Business Park, Near Gurudwara, $.G. Highway, Thaltej. Ahmedabad-380059, Gujarat, India - Tele.: +079-40233000 | Website : www.coronaremedics.com CIN : 124231G12004PLCO44656. Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30 September 2026 (Amount Rs. in Crores except pet share data)| For Quarter Ended For Half Year Ended___|For Year Ended| . Par 30 September [ 1 T30 September | 30 September [ 30 September [ 466 No. 2026 Trasiicl) 2025 2026 2025 ) (Unaudited) (Unaudited) | (Unaudited) | (Unaudited) - T |Income: Revenue from operations 44117 42243 36113 863.60 707.67 1,403.18 Other income 248 315 227 5.63 429 1065 Total income 443.65 42558 363.40 869.23 711.96 1,413.83 2 |Expenses : Cost of materials consumed 3501 32.65 25.90 67.66 50.97 10351 Purchases of Stock-in-trade 6824 5720 211 125.44 6288 150,38 |Changes in inventorics of finished goods, stock-in-trade and 270 233 . P 2058 705 work-in-progress Employee benefits expense 12424 122.09 103.00 246.33 20044 403.02 Finance costs 275 2.69 193 544 3.9 697 Depreciation and amortization expenses 15.06 1324 920 28.30 18.12 37.87 Other expenses 14047 129.69 11101 27016 224.55 445.78 ‘Total expenses 363.03 34523 293.79 | _ 581.46 115458 3 |Profit before excep [Showing first 8,000 characters — download PDF for full document]